Trial Profile
A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Milciclib (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nerviano Medical Sciences
- 16 Dec 2021 Status changed from recruiting to completed.
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record. (End date:2012-08-31)
- 09 Aug 2011 New trial record